BioSpace News Archive

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), today announced results from its ongoing Phase 2 trial of BXCL701, the Company’s investigational, oral innate immunity activator, in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype.

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that positive results from the Phase 3 PROpel trial showed LYNPARZA in combination with abiraterone plus prednisone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus abiraterone plus prednisone,

Arch Biopartners Inc., a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced that Health Canada has approved the amendment to the CATCO protocol to include its lead drug candidate, LSALT Peptide in a new dosing arm of the trial.

Pardes Biosciences, Inc. announced that interim clinical data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers has been made available to registered conference attendees at the 29th Conference on Retroviruses and Opportunistic Infections (CROI) 2022.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the fourth quarter and full year of 2021 along with recent corporate updates on February 28, 2022.

Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the third quarter of fiscal 2022 (for the three months ended December 31, 2021).

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced that it has been selected to deliver an oral presentation of preclinical data from its KIN-2787 program at the upcoming virtual IASLC 2022 Targeted Therapies of Lung Cancer meeting taking place February 22-26, 2022.

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a Phase 2b clincial trial of the mGluR5 inihibitor NOE-101 in trigeminal neuralgia (TN).

Outlook Therapeutics, Inc. announced recent corporate highlights and financial results for its fiscal first quarter ended December 31, 2021.

Benitec Biopharma Inc., a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference platform, announced the financial results for its Fiscal Year Q2 ended December 31, 2021.